Cantargia (CANTA) Corporate presentation summary

Strategic focus and platform

• Specializes in targeting IL1RAP, a co-receptor central to inflammation and cancer signaling, impacting IL-1, IL-33, and IL-36 pathways.

• Pipeline includes oncology and autoimmune programs, with nadunolimab as lead asset and CANXX platform generating next-generation constructs.

• CAN10, a key autoimmune asset, is partnered globally with Otsuka in a deal valued up to $613 million.

• Proprietary antibody library and IP portfolio provide broad coverage and long-term exclusivity.

• Executive team brings experience from major pharma and biotech companies.

Oncology pipeline and clinical data

• Nadunolimab targets IL1RAP, showing efficacy in pancreatic ductal adenocarcinoma (PDAC) and myeloid malignancies.

• High IL1RAP expression in PDAC and AML correlates with poor prognosis; nadunolimab improves survival, especially in high-expressing patients.

• In 1st line metastatic PDAC, nadunolimab plus chemotherapy achieved a 32% response rate and median OS of 13.2 months, outperforming historical controls.

• Investigator-initiated trials ongoing in AML/MDS and metastatic colorectal cancer, with promising early results.

• Nadunolimab demonstrates a favorable safety profile, with reduced neuropathy compared to standard regimens.

Autoimmune and next-generation programs

• CAN10 blocks multiple IL-1 family cytokines, showing robust preclinical efficacy in inflammatory and fibrotic diseases.

• Otsuka partnership validates the platform and provides significant non-dilutive funding and global reach.

• CANXX platform enables development of bispecific antibodies and ADCs for tailored disease targeting.

• Next-generation assets (CAN14, CANXX) are advancing toward candidate selection, expanding into dermatology, rheumatology, and respiratory indications.